PlasmaTech Biopharmaceuticals Appoints Alpha-1 Expert Robert Sandhaus, MD, Ph.D. to Its Scientific Advisory Board
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, appointed Robert Sandhaus, MD, Ph.D. to its Scientific Advisory Board (SAB). The appointed SAB will serve as a strategic resource to the company as it continues to develop and commercialize its proprietary plasma fractionation platform, Salt Diafiltration Process (SDF™), and its lead biologic candidate, SDF Alpha, its proprietary alpha-1 protease inhibitor (A1PI).
View full press release